Vlatković N - Search Results

1

p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?

Noon AP, Vlatković N, Polański R, Maguire M, Shawki H, Parsons K, Boyd MT. Noon AP, et al. Among authors: vlatkovic n. Cancer. 2010 Feb 15;116(4):780-90. doi: 10.1002/cncr.24841. Cancer. 2010. PMID: 20052733 Free PMC article. Review.

2

Regulation of p53 and MDM2 activity by MTBP.

Brady M, Vlatkovic N, Boyd MT. Brady M, et al. Among authors: vlatkovic n. Mol Cell Biol. 2005 Jan;25(2):545-53. doi: 10.1128/MCB.25.2.545-553.2005. Mol Cell Biol. 2005. PMID: 15632057 Free PMC article.

3

p53 regulation and function in renal cell carcinoma.

Warburton HE, Brady M, Vlatković N, Linehan WM, Parsons K, Boyd MT. Warburton HE, et al. Among authors: vlatkovic n. Cancer Res. 2005 Aug 1;65(15):6498-503. doi: 10.1158/0008-5472.CAN-05-0017. Cancer Res. 2005. PMID: 16061625

4

MDM2 regulates dihydrofolate reductase activity through monoubiquitination.

Maguire M, Nield PC, Devling T, Jenkins RE, Park BK, Polański R, Vlatković N, Boyd MT. Maguire M, et al. Among authors: vlatkovic n. Cancer Res. 2008 May 1;68(9):3232-42. doi: 10.1158/0008-5472.CAN-07-5271. Cancer Res. 2008. PMID: 18451149 Free PMC article.

5

MDM2 promotes cell motility and invasiveness through a RING-finger independent mechanism.

Polański R, Warburton HE, Ray-Sinha A, Devling T, Pakula H, Rubbi CP, Vlatković N, Boyd MT. Polański R, et al. Among authors: vlatkovic n. FEBS Lett. 2010 Nov 19;584(22):4695-702. doi: 10.1016/j.febslet.2010.10.049. Epub 2010 Oct 29. FEBS Lett. 2010. PMID: 21034743 Free article.

6

MDM2 interacts with NME2 (non-metastatic cells 2, protein) and suppresses the ability of NME2 to negatively regulate cell motility.

Polanski R, Maguire M, Nield PC, Jenkins RE, Park BK, Krawczynska K, Devling T, Ray-Sinha A, Rubbi CP, Vlatkovic N, Boyd MT. Polanski R, et al. Among authors: vlatkovic n. Carcinogenesis. 2011 Aug;32(8):1133-42. doi: 10.1093/carcin/bgr070. Epub 2011 Apr 18. Carcinogenesis. 2011. PMID: 21504894

7

Loss of MTBP expression is associated with reduced survival in a biomarker-defined subset of patients with squamous cell carcinoma of the head and neck.

Vlatković N, El-Fert A, Devling T, Ray-Sinha A, Gore DM, Rubbi CP, Dodson A, Jones AS, Helliwell TR, Jones TM, Boyd MT. Vlatković N, et al. Cancer. 2011 Jul 1;117(13):2939-50. doi: 10.1002/cncr.25864. Epub 2011 Jan 10. Cancer. 2011. PMID: 21692053 Free article.

8

Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy.

Noon AP, Polański R, El-Fert AY, Kalirai H, Shawki H, Campbell F, Dodson A, Eccles RM, Lloyd BH, Sibson DR, Coupland SE, Lake SL, Parsons K, Vlatković N, Boyd MT. Noon AP, et al. Among authors: vlatkovic n. BJU Int. 2012 Apr;109(8):1250-7. doi: 10.1111/j.1464-410X.2011.10433.x. Epub 2011 Jul 14. BJU Int. 2012. PMID: 21756282

9

The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer.

Thornton M, Aslam MA, Tweedle EM, Ang C, Campbell F, Jackson R, Costello E, Rooney PS, Vlatković N, Boyd MT. Thornton M, et al. Among authors: vlatkovic n. Int J Cancer. 2013 Sep 15;133(6):1408-18. doi: 10.1002/ijc.28137. Epub 2013 Apr 8. Int J Cancer. 2013. PMID: 23456958 Free article.

10

Senescence induction in renal carcinoma cells by Nutlin-3: a potential therapeutic strategy based on MDM2 antagonism.

Polański R, Noon AP, Blaydes J, Phillips A, Rubbi CP, Parsons K, Vlatković N, Boyd MT. Polański R, et al. Among authors: vlatkovic n. Cancer Lett. 2014 Oct 28;353(2):211-9. doi: 10.1016/j.canlet.2014.07.024. Epub 2014 Jul 24. Cancer Lett. 2014. PMID: 25067787

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28 results

Search Page